SCHEMBL9944095

SCHEMBL9944095

Cc1cc(C(=O)Nc2ccc(C(=O)O)c(F)c2)cc(Cl)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.52
RARB P10826 1/20 0.52
RARG P13631 1/20 0.52
CPT1A P50416 5/20 0.48
CPT1B Q92523 5/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
CPT2 P23786 4/20 0.48
AVPR2 P30518 1/20 0.46
OXTR P30559 1/20 0.46
AVPR1A P37288 1/20 0.46
PTGFR P43088 1/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944083 0.88 NPC1 (0.50) NPC1RAB9ATP53PKMKMT2A
SCHEMBL9944098 0.86 PKM (0.60) NPC1RAB9ATP53PKMKMT2A
SCHEMBL9944146 0.86 TAS1R3 (0.54) RARARARBRARGCPT1ACPT1B
SCHEMBL9944100 0.85 RARA (0.52) RARARARBRARGCPT1ACPT1B
SCHEMBL9944105 0.85 RARA (0.47) RARARARBRARGCPT1ACPT1B
SCHEMBL12825318 0.84 RARA (0.53) RARARARBRARGCPT1ACPT1B
SCHEMBL9944097 0.84 PLAU (0.47) RARARARBRARGCPT1ACPT1B
SCHEMBL9944148 0.83 RAB9A (0.58) RARARARBRARGCPT1ACPT1B
SCHEMBL9944088 0.83 NPC1 (0.53) NPC1RAB9ATP53PKMKMT2A
SCHEMBL9944079 0.81 KMT2A (0.54) RARARARBRARGCPT1ACPT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.